Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Stephen V. Liu is an Assistant Professor of Medicine and a practicing thoracic medical oncologist at the Lombardi Comprehensive Cancer Center at Georgetown University. He received his undergraduate degree at Johns Hopkins University and his medical degree at the University of Maryland. He then completed his internship and residency in Internal Medicine at the University of Pennsylvania and his fellowship training in Hematology and Oncology at the University of Southern California before joining the faculty of Georgetown University. Dr.

Targeted Therapies Forum Presented in English 2023 - Breakout Sessions
Our Targeted Therapies Forum online event includes a Q&A session where our amazing faculty answers questions from the audience. This is the first batch of videos of the Breakout Sessions.
Author
Stephen Liu, MD, GRACE Faculty
Image
Targeted Therapies Forum presented in English

This series includes videos from the breakout sessions presented by Dr. Stephen Liu and Dr. Misako Nagasaka, including the following topics:

  • Treatments and Study Data for Patients with ALK+ NSCLC
  • Treatment Options & Study Data for Patients with ROS1+ NSCLC
  • Rare Fusions in NSCLC: RET
  • RET Fusion Treatment: Selpercatinib
  • RET Fusion Treatment: Pralsetinib

To watch the complete playlist click here.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on